Glenmark Pharma Launches Adapalene Gel Pump Packs in US Acne Care Market

Key numbers

Market Cap	₹64,770.57 CrLarge Cap
Revenue TTM	₹17,736.55 CrOperating Income
P/E Ratio	36.03Sector 46.49
Day RSI	40.32Neutral Zone

Key highlights

• Launch of Adapalene Gel USP, 0.1% (OTC) in 15g and 45g pump pack formats
• Targets the $45.8 million market segment currently led by Differin Gel 0.1%
• Latest quarterly net profit surged 930.33% YoY to ₹482.92 crore
• Operating revenue for the June 2026 quarter grew 23.1% YoY to ₹4,018.48 crore
• Stock trades at a P/E TTM of 36.03 compared to the sector average of 46.49

Strategic Entry into US OTC Acne Care Segment

Glenmark’s US subsidiary has introduced Adapalene Gel USP, 0.1% (OTC) in new pump packs, specifically designed to enhance consumer convenience and ease of dispensing. This topical retinoid is used for the treatment of acne and is comparable to the active ingredient found in Differin Gel. According to Nielsen syndicated data for the 52-week period ending September 5, 2026, the specific market for this product achieved annual sales of approximately $45.8 million.

The launch expands Glenmark’s already growing dermatology portfolio in North America, where the company maintains a significant commercial footprint.

Global Launches and Capital Expenditure Outlook

• Launched RYALTRIS respiratory spray in the Brazilian market in September 2026
• Released Calcium Gluconate and Sugammadex injections in the US during Q3 2026
• Introduced Winlevi (clascoterone) 10 mg/g cream in key European markets in June 2026
• Management has guided for a capital expenditure of ₹900 crore for FY27
• Oncology trispecific antibody ISB 2001 milestone potential stands at $1.225 billion

Leadership on Enhancing US Dermatology Portfolio

The introduction of Adapalene Gel USP, 0.1% (OTC) in a new pump pack enhances consumer experience by offering a convenient and easy to use dispensing option while further strengthening our growing U.S. dermatology portfolio. This launch reflects our commitment to delivering high-quality and affordable healthcare solutions that meet evolving consumer needs.

Strong Financial Momentum in FY27

Glenmark Pharmaceuticals reported exceptional growth in the quarter ended June 30, 2026, with net profit rising by 930.33% to ₹482.92 crore compared to the same period last year. Revenue growth was also robust at 23.1%, reaching ₹4,018.48 crore. The company's operating profit margin improved to 20.03%, reflecting better efficiency.

With a Piotroski Score of 8 and a durability score of 80, the company shows strong financial health. The current market price of ₹2295 reflects a 15.9% increase over the last year, even as the stock trades 9.5% below its 52-week high.

What to watch next

• Final dividend payment of ₹2.50 per share scheduled for October 11, 2026
• Announcement of Q2 FY27 financial results in November 2026
• Potential milestone payments from the out-licensed oncology antibody ISB 2001

Glenmark Pharmaceuticals · financial snapshot

Share price	₹2295
Market capitalisation	₹64,770.57 Cr
Revenue (annual)	₹16,982.51 Cr
Net profit (annual)	₹1,361.85 Cr
Revenue (latest quarter)	₹4,018.48 Cr+6.57% vs previous quarter
Net profit (latest quarter)	₹482.92 Cr+60.22% vs previous quarter
P/E (TTM)	36.03×Sector 46.49×
Promoter holding	46.65%0.00% QoQ
FII holding	20.89%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.